MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA

Zhan, Shijuan; Wang, Chunfeng; Yin, Fangqing

doi:10.3892/mmr.2018.8678

Cited by 14 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, five differentially expressed miRNAs were all upregulated in metastatic melanoma tissues, including miRNA-29c, miRNA-100, miR-142-3p, miR-150, miR-516a-2, and the upregulation of each differential miRNA was positively correlated with patient survival time, indicating that these five miRNAs might be inhibitory factors of melanoma metastasis. In previous studies, miRNA-29c has been shown to be downregulated in prostate cancer and non-small cell lung cancer (NSCLC) [22,23]. Also, miRNA-100 [24], miR-142-3p [25] and miR-150 [26] have previously been reported to inhibit the proliferation of gastric cancer cells, liver cell cancer cells and melanoma cells in vitro , through the targeted suppression of the CXCR7, LDHA, and MYB genes, respectively.…”

Section: Discussionmentioning

confidence: 99%

Integrative Analysis of Long Noncoding RNA (lncRNA), microRNA (miRNA) and mRNA Expression and Construction of a Competing Endogenous RNA (ceRNA) Network in Metastatic Melanoma

et al. 2019

View full text Add to dashboard Cite

Worldwide, metastatic melanoma of the skin has an aggressive course with high morbidity and mortality. Therefore, an increased understanding of the pathogenesis of metastatic melanoma has gained increasing attention, including the role of epigenetic modification and competing endogenous RNA (ceRNA). This study aimed to used bioinformatics data to undertake an integrative analysis of long noncoding RNA (lncRNA), microRNA (miRNA) and mRNA expression to construct a ceRNA network in metastatic melanoma. Data from the Cancer Genome Atlas (TCGA), the Gene Ontology (GO) database, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were analyzed. There were 471 cases that included 103 primary solid tumors and 368 cases of metastatic melanoma that included transcriptome sequencing data (including lncRNA and mRNA); 452 cases had miRNA sequencing data. Analysis of chip data identified 85 6 mRNAs, 67 miRNAs, and 250 lncRNAs that were differentially expressed in cases of metastatic melanoma, of which 25 miRNAs, 18 lncRNAs, and 18 mRNAs participated in the formation of ceRNAs. Survival analysis identified seven differentially expressed mRNAs, five differentially expressed miRNAs (miRNA-29c, miRNA-100, miR-142-3p, miR-150, miR-516a-2), and six differentially expressed lncRNAs (AC068594.1, C7orf71, FAM41C, GPC5-AS1, MUC19, LINC00402) that were correlated with survival time in patients with metastatic melanoma. Bioinformatics data and integrative analysis identified lncRNA, miRNA, and mRNA expression to construct a ceRNA and patient survival network in metastatic melanoma. These findings support the need for further studies on the mechanisms involved in the regulation of metastatic melanoma by ceRNAs.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrative Analysis of Long Noncoding RNA (lncRNA), microRNA (miRNA) and mRNA Expression and Construction of a Competing Endogenous RNA (ceRNA) Network in Metastatic Melanoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…S9). However, miR-29c and miR-30b were shown as tumor suppressor miRNAs in lung cancer [17,[28][29][30][31][32][33]. Oncogenes such as myc, gli, and NF-κb can bind to the promotor region of miR-29c to suppress its transcription in cholangiocarcinoma cells [34].…”

Section: Discussionmentioning

confidence: 99%

Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer

Yang

Zhang

et al. 2019

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Despite decades of efforts, non-small-cell lung cancer (NSCLC) remains the leading cause of cancer mortality globally primarily due to the challenge in early detection of the cancer. Being an important player in cancer development, the dysregulated miRNAs have been shown promising values as non-invasive diagnostic and prognostic biomarkers for NSCLC. The aim of our study is to access the efficacy and reliability of a potential circulating miRNA panel in early diagnosis of NSCLC. We first selected eight candidate miRNAs, miR-146b, miR-205, miR-29c, miR-31, miR-30b, miR-337, miR-411, and miR-708, which have been shown frequently aberrant in primary NSCLC patients based on our previous studies and other reports. The serum level of each of these miRNAs was evaluated by quantitative real-time PCR (qRT-PCR) in training and testing sets. We found that 5 out of 8 miRNAs (miR-146b, miR-205, miR-29c, miR-30b, and miR-337) were significantly up-regulated in NSCLCs patients compared to healthy or cancer-free controls in both training and testing sets. Based on the logistic regression model, a 4-miRNAs set (miR-146b, miR-205, miR-29c and miR-30b) was picked out of the 5 miRNAs owing to its excellent diagnostic power for NSCLC patients in the training set (AUC=0.99, accuracy=95.00%), the testing set (AUC=0.93, accuracy=89.69%), and the training-testing combined set ( AUC=0.96, accuracy=92.00%). When pathological subtypes of NSCLC are compared, this 4-miRNA panel carried a relatively higher prediction power and higher sensitivity for adenocarcinoma (AC) (AUC=0.98, sensitivity=99.10%) than for squamous cell carcinoma (SCC) (AUC=0.93, sensitivity=90.32%). Additionally, this panel demonstrated a comparable diagnostic capacity for stage I (AUC=0.96) and stage II-III (AUC=0.95) of NSCLC, suggesting its role in reflecting the tumor load. Importantly, the high levels of miR-146b and miR-29c in serum were significantly associated with poor 5-year overall survival (OS) (both p=0.04). Further survival analysis showed that high level of miR-146b in serum is specifically correlated with poor survival rate in SCC patients (p=0.0035) but not in AC patients (p=0.83), consistent with our previous finding that the high tissue expression of miR-146b in lung cancer specimen is indicative of a poor prognosis for SCC patients. Altogether, our study demonstrated that the 4-miRNA panel is a novel, sensitive and non-invasive serum marker for the early diagnosis of NSCLC.

show abstract

“… 16 The 5-year survival rate of lung cancer is poor due to the high invasion and metastasis of tumors. 3 In recent years, multiple miRNAs have been reported to play a functional role in the occurrence and progression of lung cancer. 5 The present study explored the effects of miR-210-3p on cell viability, migration, invasion, and apoptosis in lung cancer.…”

Section: Discussionmentioning

confidence: 99%

“… 2 For instance, miR-29c regulates cell proliferation and cellular apoptosis that in turn affects the tumor progression of NSCLC. 3 Existing literature reported that miR-18a-5p is upregulated in NSCLC, and it promotes cell proliferation and migration, tumor growth, and metastasis of NSCLC both in vitro and in vivo to aggravate lung cancer. 17 miR-210 is also shown to play a significant role in a variety of tumor biological functions, including tumor proliferation, survival, and metastasis via regulation of target genes.…”

Section: Discussionmentioning

confidence: 99%

“… 2 The incidence rate of lung cancer is rising, and the prognosis is poor. 3 In the recent three decades, the 5-year survival of patients with lung cancer remains only 19%, with minimal improvement. 4 Thus, it is imperative to explore the underlying molecular mechanisms and identify the novel prognostic biomarkers and potential therapeutic targets for lung cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miR-210-3p Promotes Lung Cancer Development and Progression by Modulating USF1 and PCGF3

Chen

Zhang

et al. 2021

OTT

View full text Add to dashboard Cite

Lung cancer represents one of the most frequent solid tumors. Adenocarcinoma is a common type of tumor and a significant threat to individual health globally. MicroRNAs (miRNAs) are recognized as critical governors of gene expression during carcinogenesis, while their effects on lung cancer occurrence and development are required for further investigation. Herein, the functional role of miR-210-3p and its regulation mechanism were characterized in lung cancer. Methods: A total of 50 pairs of tumor and tumor-free lung tissues were surgically resected from lung cancer patients. Dual-luciferase reporter assay and RNA immunoprecipitation assay were performed to examine USF1 binding with miR-210-3p and PCGF3. Cultured human lung cancer cells A549 were assayed for viability, apoptosis, migration, and invasion in vitro by CCK-8 test, flow cytometry, transwell chamber assays, tumorigenesis, and lymph node metastasis in vivo by mouse xenograft experiments. Results: miR-210-3p was upregulated in lung cancer tissues. The inhibition of miR-210-3p by specific inhibitor tempered lung cancer development and metastasis in vitro and in vivo. miR-210-3p targeted USF1 and inhibited its expression. USF1 was bound with PCGF3, which increased its transcription. PCGF3-specific knockdown mimicked the effect of miR-210-3p on lung cancer development and metastasis in vitro and in vivo. Conclusion:The current study demonstrated that miR-210-3p facilitates lung cancer development and metastasis by impairing USF1-mediated promotion of PCGF3, which provides a better understanding of the mechanism of lung cancer development and metastasis.

show abstract

MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA

Cited by 14 publications

References 24 publications

Integrative Analysis of Long Noncoding RNA (lncRNA), microRNA (miRNA) and mRNA Expression and Construction of a Competing Endogenous RNA (ceRNA) Network in Metastatic Melanoma

Integrative Analysis of Long Noncoding RNA (lncRNA), microRNA (miRNA) and mRNA Expression and Construction of a Competing Endogenous RNA (ceRNA) Network in Metastatic Melanoma

Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer

miR-210-3p Promotes Lung Cancer Development and Progression by Modulating USF1 and PCGF3

Contact Info

Product

Resources

About